Page 14 - Sun Pharma

Sun Pharma aims to clock 'low-to-mid teens' growth in revenues in FY20

Drug major Sun Pharmaceutical Industries is gradually ramping up its speciality business across global markets as it aims to clock "low-to-mid teens" growth in consolidated revenues in the current fiscal. Addressing shareholders in the company's annual report for 2018-19, Sun Pharma Managing Director Dilip Shanghvi said the company is focused at growing each of its business verticals faster than the market in which it operates. "Our consistent focus is on growing each of our businesses faster than the market in which they operate. Our global specialty initiatives will supplement this objective as an additional growth engine," Shanghvi said. The company is targeting key ailments like psoriasis to gradually ramp up its global specialty business, he said adding that Sun Pharma would continue to invest in branding and promotion of its various specialty products. Besides, R&D investments for funding clinical trials of some of the specialty products are also likely to continue in ...

Sun Pharma bets on nurturing specialty portfolio outlook; stock rises 3.6%

Street is bullish on stabilising US generics sales, upsides from niche portfolio, and inexpensive valuations

Sun Pharma gains for fifth straight day on Morgan Stanley's upgrade

In the past one week, Sun Pharma has outperformed the market by surging 16 per cent, as compared to 0.20 per cent decline in the S&P BSE Sensex

Sun Pharma launches drug in US to treat lipid-linked swallowing problems

Ezallor Sprinkle (rosuvastatin) capsules is indicated for three types of lipid disorders in conjunction with diet in adults

Five reasons why Morgan Stanley has turned bullish on Sun Pharma

The global brokerage firm said Sun Pharma was its top pick in its Indian healthcare coverage and sees 27 per cent upside potential in the stock

Sun Pharmaceutical gets four observations for Halol facility in Gujarat

The regulator has also observed that lab control mechanisms were not documented

Sun Pharma Q4 profit halves to Rs 636 cr on distribution strategy change

Sales in the US were $443 million for the quarter, a 20 per cent increase over the same period last year, and accounted for 44 per cent of total sales

Street positive on Sun Pharma's health despite disappointing Q4 results

US litigation issues remain the firm's Achilles heel

Sun Pharma Q4 net profit at Rs 635.88 crore; sales in US jump 20%

The company had posted a net profit of Rs 1,342.50 crore for the corresponding period of the previous fiscal

Looking beyond generic, Sun Pharma plans to develop its own medicines

After a 4-yr decline that erased 65% from the value of Sun, Shanghvi is preparing to bounce back

We have big expectations from Japan and China: Sun Pharma's Dilip Shanghvi

Shangvi feels the domestic market is big enough to accommodate both branded and unbranded medicines

China's war on healthcare costs lures India's biggest drugmaker Sun Pharma

The policy push comes as many generic drugmakers are still reeling from a brutal price war in the world's biggest drug market, the US.

USFDA issues Form 483 to Sun Pharma's Dadra plant over quality issues

As per media reports, the regulator is learnt to have found deficiencies relating to medicine quality, data collection, maintenance as well as quality control unit

Sun Pharma slips nearly 2% in an otherwise strong market

The pharma company had reported a nearly four-fold jump in its consolidated net profit at Rs 1,241.85 crore for the third quarter of financial year 2018-19(FY18-19).

Sun Pharma net profit up four-fold to Rs 1,242 crore in Dec quarter

The company may also spend more on research and development (R&D) next year owing to clinical trials for new indications of its recently launched product Ilumya and others

Sun Pharma reports nearly four-fold jump in Q3 net profit at Rs 1,242 cr

The company had posted a net profit of Rs 321.57 crore for the corresponding period of the previous fiscal

Sun Pharma promoter meets Sebi chief to clarify on whistleblower complaint

Dilip Shanghvi clarifies stance on various allegations, claims mala fide campaign against him and firm

Sun Pharma to settle Dubai firm loans, shift distribution arm to subsidiary

Sun Pharma in damage control mode after stock loses about 30% of its value since Sept due to corporate governance concerns

Sun Pharma takes steps to ease governance concerns; shares rally over 6%

The move comes after its shares tumbled last week following reports about a complaint by a whistleblower to regulators relating to certain transactions involving the company and an executive director

Sun Pharma jumps 5% on series of clarifications

The drug major said that its domestic formulations distribution shall be transitioned from Aditya Medisales, the current distributor, to a wholly-owned subsidiary of Sun Pharma.